A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results

Cancer

Volumn 119, Issue 3, 2013, Pages 540-547

  Siefker Radtke, Arlene O ^a   Dinney, Colin P ^b   Shen, Yu ^b   Williams, Dallas L ^a   Kamat, Ashish M ^b   Grossman, H Barton ^b   Millikan, Randall E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

bladder cancer; chemotherapy; clinical trial; doxorubicin; gemcitabine; ifosfamide; neoadjuvant; sequential; surgery; urothelial cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MESNA;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CATHETER THROMBOSIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CYSTECTOMY; CYSTOSCOPY; DEHYDRATION; DISEASE SPECIFIC SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; ERYTHROCYTE DISORDER; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HALLUCINATION; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HYDRONEPHROSIS; INFECTION; LOW DRUG DOSE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROURETERECTOMY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOCYTE DISORDER; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84872981467     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27751     Document Type: Article

References (14)

1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [see comment; erratum appears in N Engl J Med. 2003;349:1880]. N Engl J Med. 2003; 349: 859-866.
2. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-2177.
3. Bajorin DF,. Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol. 2001; 19 (18 suppl): 17S-20S.
4. Sternberg CN, Parmar MK,. Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol. 2001; 19 (18 suppl): 21S-26S.
5. Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009; 27: 4062-4067.
6. Logothetis CJ, Siefker-Radtke A,. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol. 2010; 57: 728-729.
7. Siefker-Radtke AO, Kamat AM, Williams DL, et al. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: final results from the M. D. Anderson Cancer Center [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 5071.
8. Plunkett W, Ghandi, V,. Nucleoside analogs: cellular pharmacology, mechanisms of action and strategies for combination therapy. In:, Cheson BKM, Plunkett W, eds. Nucleoside Analogs in Cancer Therapy. New York: Marcel Dekker, Inc.; 1997: 1-35.
9. Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ,. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer. 2001; 92: 194-199.
10. Pagliaro LC, Millikan RE, Tu SM, et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002; 20: 2965-2970.
11. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 4005-4013.
12. Simon R,. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
13. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: 4104-4109.
14. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004; 171 (2 pt 1): 570-574.